Skip to main content
Erschienen in: Clinical and Translational Oncology 2/2023

04.10.2022 | Research Article

Machine learning-based automated planning for hippocampal avoidance prophylactic cranial irradiation

verfasst von: Rodríguez de Dios N, Martínez Moñino A, Cristina Liu, Rafael Jiménez, Núria Antón, Miguel Prieto, Francesco Amorelli, Palmira Foro, Manuel Algara, Xavier Sanz, Ismael Membrive, Ana Reig, Jaume Quera, Enric Fernández-Velilla, Oscar Pera

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Design and evaluate a knowledge-based model using commercially available artificial intelligence tools for automated treatment planning to efficiently generate clinically acceptable hippocampal avoidance prophylactic cranial irradiation (HA-PCI) plans in patients with small-cell lung cancer.

Materials and methods

Data from 44 patients with different grades of head flexion (range 45°) were used as the training datasets. A Rapid Plan knowledge-based planning (KB) routine was applied for a prescription of 25 Gy in 10 fractions using two volumetric modulated arc therapy (VMAT) arcs. The 9 plans used to validate the initial model were added to generate a second version of the RP model (Hippo-MARv2). Automated plans (AP) were compared with manual plans (MP) according to the dose-volume objectives of the PREMER trial. Optimization time and model quality were assessed using 10 patients who were not included in the first 44 datasets.

Results

A 55% reduction in average optimization time was observed for AP compared to MP. (15 vs 33 min; p = 0.001).Statistically significant differences in favor of AP were found for D98% (22.6 vs 20.9 Gy), Homogeneity Index (17.6 vs 23.0) and Hippocampus D mean (11.0 vs 11.7 Gy). The AP met the proposed objectives without significant deviations, while in the case of the MP, significant deviations from the proposed target values were found in 2 cases.

Conclusion

The KB model allows automated planning for HA-PCI. Automation of radiotherapy planning improves efficiency, safety, and quality and could facilitate access to new techniques.
Literatur
1.
4.
Zurück zum Zitat Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, et al. Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:77–84. https://doi.org/10.1016/j.ijrobp.2010.05.013.CrossRef Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, et al. Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:77–84. https://​doi.​org/​10.​1016/​j.​ijrobp.​2010.​05.​013.CrossRef
7.
Zurück zum Zitat Rodríguez de Dios N, Couñago F, Murcia-Mejía M, Rico-Oses M, Calvo-Crespo P, Samper P, et al. Randomized phase iii trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): A GICOR-GOECP-SEOR study. J Clin Oncol. 2021;39:3118–27. https://doi.org/10.1200/JCO.21.00639.CrossRef Rodríguez de Dios N, Couñago F, Murcia-Mejía M, Rico-Oses M, Calvo-Crespo P, Samper P, et al. Randomized phase iii trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): A GICOR-GOECP-SEOR study. J Clin Oncol. 2021;39:3118–27. https://​doi.​org/​10.​1200/​JCO.​21.​00639.CrossRef
12.
13.
Zurück zum Zitat Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, for NRG Oncology, et al. Hippocampal avoidance during whole brain radiotheraphy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001. J Clin Oncol. 2020;38:1019–29.CrossRef Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, for NRG Oncology, et al. Hippocampal avoidance during whole brain radiotheraphy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001. J Clin Oncol. 2020;38:1019–29.CrossRef
14.
Zurück zum Zitat Das IJ, Cheng C-W, Chopra KL, Mitra RK, Srivastava SP, Glatstein E. Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems. J Natl Cancer Inst. 2008;100:300–7. https://doi.org/10.1093/jnci/djn020.CrossRef Das IJ, Cheng C-W, Chopra KL, Mitra RK, Srivastava SP, Glatstein E. Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems. J Natl Cancer Inst. 2008;100:300–7. https://​doi.​org/​10.​1093/​jnci/​djn020.CrossRef
17.
Metadaten
Titel
Machine learning-based automated planning for hippocampal avoidance prophylactic cranial irradiation
verfasst von
Rodríguez de Dios N
Martínez Moñino A
Cristina Liu
Rafael Jiménez
Núria Antón
Miguel Prieto
Francesco Amorelli
Palmira Foro
Manuel Algara
Xavier Sanz
Ismael Membrive
Ana Reig
Jaume Quera
Enric Fernández-Velilla
Oscar Pera
Publikationsdatum
04.10.2022
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 2/2023
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-022-02963-z

Weitere Artikel der Ausgabe 2/2023

Clinical and Translational Oncology 2/2023 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.